Média

Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor

Biomarkers correlated to tumoral sensitivity to AsiDNA™, supporting personalized medicine approaches A selection tool to screen patients in future clinical development of AsiDNA™ based on these predictive biomarkers of response   Paris (France), January 3, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development…read more →

Onxeo Announces its Financial Agenda for 2019

Paris (France), December 20, 2018 – 07:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced its financial agenda for 2019. Event Date* Full-year 2018 results Tuesday, March 12, 2019 Shareholders’ general meeting…read more →

Onxeo receives EPO Intent-to-Grant Notice for new patent protecting AsiDNA™ in combination with any PARP inhibitor

Combination patent to be granted in Europe until 2036   Paris (France), December 18, 2018 – 8.30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced having been notified by the European Patent Office…read more →

Onxeo Reports Decision from the Paris Court of Appeal in the Lawsuit against SpeBio/SpePharm

Paris (France), December 13, 2018 – 7 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, reports the Decision rendered by the Court of Appeal of Paris in the litigation which started in 2009 between Onxeo…read more →

Intervention of Judith Greciet at Les Echos/Investir

November 21, 2018 : Intervention of Judith Greciet at Les Echos/Investir – Boursocap event (only in French)

Onxeo – réunion BoursoCap – 21 novembre 2018 from BoursoCap on Vimeo.

Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNA™, a First-In-Class DNA Damage Response Inhibitor

Robust biological target engagement in patient tumor cells confirms the activity of AsiDNA™ when administered intravenously Favorable safety profile with no drug-related serious adverse event and no dose-limiting toxicity Company intends to expand AsiDNA™ clinical program in combination in targeted indications as soon as H1 2019 Company to host a conference call for analysts and investors today at 5.30 pm…read more →

Onxeo Reports Third Quarter Financial Information and Provides Business Update

    AsiDNA™ clinical development progressing to plan First safety and activity results of the phase I DRIIV-1 study expected in Q4 2018 Phase Ib/IIa combination studies of AsiDNA™ to be initiated as early as H1 2019     New first-in-class compound from PlatON™, expected before end 2018, will enter preclinical testing in 2019     Cash position of €13 million at September…read more →

Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019

Paris, October 18, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced that the Company was invited to present an overview of AsiDNA™ for the treatment of solid tumors at…read more →

Onxeo to Present at the 11th Edition of the “Rencontres de la Cancérologie Française” Oncology Conference

Paris, October 3, 2018 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced its participation in the 11th edition of the Rencontres de la Cancérologie Française (RCFr), a major event dedicated to innovation in…read more →

Onxeo to attend Key Investor and Partnering Conferences in the Coming Months

Paris (France), September 13, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, today announced that its management team will attend the following key investor and partnering conferences in the coming months: European Large & Midcap Event October 8-9, 2018 Paris,…read more →

Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook

Clinical development of Onxeo’s lead product candidate AsiDNA™ progressing to plan Preliminary safety and activity results of DRIIV-1 study are expected in Q4 2018 Two combination clinical trials with AsiDNA™ planned for early 2019 New optimized candidate from platON™ proprietary platform ready to enter preclinical stage by end 2018 Cash position of €11m at June 30, 2018 enables an expanded…read more →

New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors

AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model of triple negative breast cancer resistant to PARP inhibitors AsiDNA™ combined with olaparib inhibited tumor growth in an in vivo model of ovarian cancer resistant to olaparib AsiDNA™ combined with various PARP inhibitors prevented the occurrence of resistance and reversed…read more →

Onxeo Implements an Equity Line Financing Including an Incentive Program with Nice & Green SA

Cash for Operations Extended to Q3 2020 Paris (France), June 15, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announces the initiation of an equity financing line through the issuance of…read more →